Aveo-Astellas kidney cancer drug is not recommended by FDA advisers

05/3/2013 | Yahoo

An FDA advisory panel voted 13-1 against recommending approval of Aveo Pharmaceuticals and Astellas Pharma's tivozanib as treatment for kidney cancer, citing inconsistent data from a clinical trial. The panel said another trial would be needed. Though disappointed with the decision, Aveo and Astellas said they would consult with the agency to address the advisers' concerns.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC